Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Qiagen (QGEN) Cash & Equivalents (2016 - 2025)

Qiagen's Cash & Equivalents history spans 16 years, with the latest figure at $663.6 million for Q4 2024.

  • For Q4 2024, Cash & Equivalents fell 0.68% year-over-year to $663.6 million; the TTM value through Dec 2024 reached $663.6 million, down 0.68%, while the annual FY2024 figure was $663.6 million, 0.68% down from the prior year.
  • Cash & Equivalents for Q4 2024 was $663.6 million at Qiagen, down from $668.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $880.5 million in Q4 2021 and bottomed at $598.0 million in Q4 2020.
  • The 5-year median for Cash & Equivalents is $668.1 million (2023), against an average of $708.2 million.
  • The largest annual shift saw Cash & Equivalents soared 47.25% in 2021 before it decreased 17.02% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $598.0 million in 2020, then surged by 47.25% to $880.5 million in 2021, then dropped by 17.02% to $730.7 million in 2022, then fell by 8.57% to $668.1 million in 2023, then decreased by 0.68% to $663.6 million in 2024.
  • Per Business Quant, the three most recent readings for QGEN's Cash & Equivalents are $663.6 million (Q4 2024), $668.1 million (Q4 2023), and $730.7 million (Q4 2022).